TY - JOUR
T1 - Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests
AU - Nobbenhuis, Marielle A E
AU - Bancroft, Elizabeth
AU - Moskovic, Eleanor
AU - Lennard, Fiona
AU - Pharoah, Paul
AU - Jacobs, Ian
AU - Ward, Ann
AU - Barton, Desmond P J
AU - Ind, Thomas E J
AU - Shepherd, John H.
AU - Bridges, Jane E.
AU - Gore, Martin
AU - Haracopos, Chris
AU - Shanley, Susan
AU - Ardern-Jones, Audrey
AU - Thomas, Sarah
AU - Eeles, Ros
PY - 2011/11/23
Y1 - 2011/11/23
N2 - Background: We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer.Methods: 545 women with a positive family history of ovarian cancer referred to the Ovarian Screening Service at the Royal Marsden Hospital, London from January 2000- December 2008 were included. They were stratified into three risk-groups according to family history (high-, moderate- and low-risk) of developing ovarian cancer and offered annual serum CA 125 and transvaginal ultrasound screening. The high-risk group was offered genetic testing.Results: The median age at entry was 44 years. The number of women in the high, moderate and low-risk groups was 397, 112, and 36, respectively. During 2266 women years of follow-up two ovarian cancer cases were found: one advanced stage at her fourth annual screening, and one early stage at prophylactic bilateral salpingo-oophorectomy (BSO). Prophylactic BSO was performed in 138 women (25.3%). Forty-three women had an abnormal CA125, resulting in 59 repeat tests. The re-call rate in the high, moderate and low-risk group was 14%, 3% and 6%. Equivocal transvaginal ultrasound results required 108 recalls in 71 women. The re-call rate in the high, moderate, and low-risk group was 25%, 6% and 17%.Conclusion: No early stage ovarian cancer was picked up at annual screening and a significant number of re-calls for repeat screening tests was identified. © 2011 Nobbenhuis et al; licensee BioMed Central Ltd.
AB - Background: We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer.Methods: 545 women with a positive family history of ovarian cancer referred to the Ovarian Screening Service at the Royal Marsden Hospital, London from January 2000- December 2008 were included. They were stratified into three risk-groups according to family history (high-, moderate- and low-risk) of developing ovarian cancer and offered annual serum CA 125 and transvaginal ultrasound screening. The high-risk group was offered genetic testing.Results: The median age at entry was 44 years. The number of women in the high, moderate and low-risk groups was 397, 112, and 36, respectively. During 2266 women years of follow-up two ovarian cancer cases were found: one advanced stage at her fourth annual screening, and one early stage at prophylactic bilateral salpingo-oophorectomy (BSO). Prophylactic BSO was performed in 138 women (25.3%). Forty-three women had an abnormal CA125, resulting in 59 repeat tests. The re-call rate in the high, moderate and low-risk group was 14%, 3% and 6%. Equivocal transvaginal ultrasound results required 108 recalls in 71 women. The re-call rate in the high, moderate, and low-risk group was 25%, 6% and 17%.Conclusion: No early stage ovarian cancer was picked up at annual screening and a significant number of re-calls for repeat screening tests was identified. © 2011 Nobbenhuis et al; licensee BioMed Central Ltd.
KW - Bilateral salpingo-oophorectomy
KW - Brca gene mutation
KW - Ovarian cancer
KW - Screening
KW - Serum ca125
KW - Transvaginal ultrasound
U2 - 10.1186/1897-4287-9-11
DO - 10.1186/1897-4287-9-11
M3 - Article
C2 - 22112691
SN - 1731-2302
VL - 9
JO - Hereditary cancer in clinical practice
JF - Hereditary cancer in clinical practice
IS - 1
M1 - 11
ER -